Exact Sciences Co. (NASDAQ:EXAS) Receives $71.94 Average Price Target from Brokerages

Exact Sciences Co. (NASDAQ:EXAS) has earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eighteen have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $71.94.

Several equities analysts have weighed in on EXAS shares. Jefferies Financial Group lifted their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Piper Sandler lowered their price target on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Bank of America lowered their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Finally, BTIG Research increased their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th.

Institutional Trading of Exact Sciences

Several large investors have recently made changes to their positions in the stock. Capital World Investors lifted its holdings in Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock worth $985,439,000 after purchasing an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock valued at $323,669,000 after purchasing an additional 2,462,165 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of Exact Sciences by 25.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company’s stock worth $239,922,000 after buying an additional 876,985 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Exact Sciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company’s stock worth $175,165,000 after buying an additional 16,828 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in shares of Exact Sciences by 107.7% during the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock worth $164,037,000 after buying an additional 1,513,873 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Down 2.4 %

Shares of NASDAQ EXAS opened at $47.63 on Thursday. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a market cap of $8.85 billion, a price-to-earnings ratio of -8.55 and a beta of 1.24. The business has a fifty day simple moving average of $53.52 and a 200-day simple moving average of $59.60.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Sell-side analysts predict that Exact Sciences will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.